Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Kforce (NASDAQ: KFRC) reported first quarter EPS of $0.82, in line with the analyst estimate of $0.82. Revenue for the quarter came in at $406M versus the consensus estimate of $411.56M.
Guidance
Kforce sees Q2 2023 EPS of $0.94-$1.02 versus the analyst consensus of $0.98.
Kforce sees Q2 2023 revenue of $392.00M-$400.00M versus the analyst consensus of $413.30M.
Kforce's stock price closed at $55.44. It is down -4.81% in the last 3 months and down -23.27% in the last 12 months.
Kforce saw 2 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Kforce's stock price’s past reactions to earnings here.
According to InvestingPro, Kforce's Financial Health score is "great performance".
Check out Kforce's recent earnings performance, and Kforce's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar